Elevated pretreatment serum levels of IL-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience

Simonetta Viviani, P. Notti, V. Bonfante, P. Verderio, P. Valagussa, G. Bonadonna

Research output: Contribution to journalArticle

Abstract

Alterated cytokine secretion may play a role in determining Hodgkin's disease-related immunosuppression. The aim of this study was to analyze the clinical significance of interleukin-10 (IL-10) serum levels in 73 chemotherapy-naive patients with Hodgkin's disease. We evaluated the relationship between pretreatment circulating values of IL-10 and both the clinical characteristics of the disease as well as the prognosis in terms of freedom from progression and overall survival. Abnormally high pre-treatment serum levels (mean ± standard error: 26.79 ± 13.24 pg/ml) were detected in 33/73 (45%) patients. The percentage of patients with enhanced IL-10 secretion was significantly higher in the presence of advanced disease (56% vs 32%, P <0.03), systemic symptoms (57% vs 34%, P <0.04) and more than 3 involved sites (61% vs 36%, P <0.03). The high basal levels of IL-10 negatively influenced long-term results: at 8-years freedom from progression (FFP) and overall survival (OS) for patients with IL-10>6 pg/ml vs ≤ 6 pg/ml were 69% and 76% vs 97.5% and 95%, respectively. The multivariate analysis confirmed the prognostic value of IL-10 basal serum levels (FFP, P= 0.0001; OS, P= 0.06). Our study suggests that high pre-treatment circulating levels of IL-10 are associated with a poor prognosis, irrespective of other common prognostic variables.

Original languageEnglish
Pages (from-to)59-63
Number of pages5
JournalMedical Oncology
Volume17
Issue number1
Publication statusPublished - 2000

Fingerprint

Hodgkin Disease
Interleukin-10
Serum
Neoplasms
Immunosuppression
Multivariate Analysis
Cytokines
Drug Therapy
Survival
Therapeutics

Keywords

  • Citokines
  • Hodgkin's disease
  • IL-10
  • Malignant lymphomas
  • Outcome

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Elevated pretreatment serum levels of IL-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience. / Viviani, Simonetta; Notti, P.; Bonfante, V.; Verderio, P.; Valagussa, P.; Bonadonna, G.

In: Medical Oncology, Vol. 17, No. 1, 2000, p. 59-63.

Research output: Contribution to journalArticle

@article{a3660becf0a34ee4811d6cad6b6f3fc7,
title = "Elevated pretreatment serum levels of IL-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience",
abstract = "Alterated cytokine secretion may play a role in determining Hodgkin's disease-related immunosuppression. The aim of this study was to analyze the clinical significance of interleukin-10 (IL-10) serum levels in 73 chemotherapy-naive patients with Hodgkin's disease. We evaluated the relationship between pretreatment circulating values of IL-10 and both the clinical characteristics of the disease as well as the prognosis in terms of freedom from progression and overall survival. Abnormally high pre-treatment serum levels (mean ± standard error: 26.79 ± 13.24 pg/ml) were detected in 33/73 (45{\%}) patients. The percentage of patients with enhanced IL-10 secretion was significantly higher in the presence of advanced disease (56{\%} vs 32{\%}, P <0.03), systemic symptoms (57{\%} vs 34{\%}, P <0.04) and more than 3 involved sites (61{\%} vs 36{\%}, P <0.03). The high basal levels of IL-10 negatively influenced long-term results: at 8-years freedom from progression (FFP) and overall survival (OS) for patients with IL-10>6 pg/ml vs ≤ 6 pg/ml were 69{\%} and 76{\%} vs 97.5{\%} and 95{\%}, respectively. The multivariate analysis confirmed the prognostic value of IL-10 basal serum levels (FFP, P= 0.0001; OS, P= 0.06). Our study suggests that high pre-treatment circulating levels of IL-10 are associated with a poor prognosis, irrespective of other common prognostic variables.",
keywords = "Citokines, Hodgkin's disease, IL-10, Malignant lymphomas, Outcome",
author = "Simonetta Viviani and P. Notti and V. Bonfante and P. Verderio and P. Valagussa and G. Bonadonna",
year = "2000",
language = "English",
volume = "17",
pages = "59--63",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press Inc.",
number = "1",

}

TY - JOUR

T1 - Elevated pretreatment serum levels of IL-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience

AU - Viviani, Simonetta

AU - Notti, P.

AU - Bonfante, V.

AU - Verderio, P.

AU - Valagussa, P.

AU - Bonadonna, G.

PY - 2000

Y1 - 2000

N2 - Alterated cytokine secretion may play a role in determining Hodgkin's disease-related immunosuppression. The aim of this study was to analyze the clinical significance of interleukin-10 (IL-10) serum levels in 73 chemotherapy-naive patients with Hodgkin's disease. We evaluated the relationship between pretreatment circulating values of IL-10 and both the clinical characteristics of the disease as well as the prognosis in terms of freedom from progression and overall survival. Abnormally high pre-treatment serum levels (mean ± standard error: 26.79 ± 13.24 pg/ml) were detected in 33/73 (45%) patients. The percentage of patients with enhanced IL-10 secretion was significantly higher in the presence of advanced disease (56% vs 32%, P <0.03), systemic symptoms (57% vs 34%, P <0.04) and more than 3 involved sites (61% vs 36%, P <0.03). The high basal levels of IL-10 negatively influenced long-term results: at 8-years freedom from progression (FFP) and overall survival (OS) for patients with IL-10>6 pg/ml vs ≤ 6 pg/ml were 69% and 76% vs 97.5% and 95%, respectively. The multivariate analysis confirmed the prognostic value of IL-10 basal serum levels (FFP, P= 0.0001; OS, P= 0.06). Our study suggests that high pre-treatment circulating levels of IL-10 are associated with a poor prognosis, irrespective of other common prognostic variables.

AB - Alterated cytokine secretion may play a role in determining Hodgkin's disease-related immunosuppression. The aim of this study was to analyze the clinical significance of interleukin-10 (IL-10) serum levels in 73 chemotherapy-naive patients with Hodgkin's disease. We evaluated the relationship between pretreatment circulating values of IL-10 and both the clinical characteristics of the disease as well as the prognosis in terms of freedom from progression and overall survival. Abnormally high pre-treatment serum levels (mean ± standard error: 26.79 ± 13.24 pg/ml) were detected in 33/73 (45%) patients. The percentage of patients with enhanced IL-10 secretion was significantly higher in the presence of advanced disease (56% vs 32%, P <0.03), systemic symptoms (57% vs 34%, P <0.04) and more than 3 involved sites (61% vs 36%, P <0.03). The high basal levels of IL-10 negatively influenced long-term results: at 8-years freedom from progression (FFP) and overall survival (OS) for patients with IL-10>6 pg/ml vs ≤ 6 pg/ml were 69% and 76% vs 97.5% and 95%, respectively. The multivariate analysis confirmed the prognostic value of IL-10 basal serum levels (FFP, P= 0.0001; OS, P= 0.06). Our study suggests that high pre-treatment circulating levels of IL-10 are associated with a poor prognosis, irrespective of other common prognostic variables.

KW - Citokines

KW - Hodgkin's disease

KW - IL-10

KW - Malignant lymphomas

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=0034059443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034059443&partnerID=8YFLogxK

M3 - Article

C2 - 10713662

AN - SCOPUS:0034059443

VL - 17

SP - 59

EP - 63

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 1

ER -